查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1672817

慢性阻塞性肺病(COPD) 治疗市场按药物类别、给药途径、通路和地区划分

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 178 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2025 年全球慢性阻塞性肺病(COPD) 治疗市场规模估计为 203.5 亿美元，预计到 2032 年将达到 304.1 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 5.9%。

报告范围 报告详细信息
基准年 2024 2025 年市场规模 203.5亿美元
效能资料 从 2020 年到 2024 年 预测期 2025 至 2032 年
预测期：2025-2032年复合年增长率： 5.90％ 2032 年价值预测 304.1亿美元
数字。 2025 年慢性阻塞性肺病(COPD) 治疗市场占有率（按地区）
慢性阻塞性肺病 (COPD) 治疗市场-IMG1

慢性阻塞性肺病(COPD) 是指一组导致气流阻塞和呼吸问题的肺部疾病。这些包括肺气肿和慢性支气管炎。慢性阻塞性肺病的主要原因包括吸烟、接触职场的灰尘和烟雾等肺部刺激物以及空气污染。 COPD 的主要症状包括呼吸短促、咳嗽、黏液（痰）和喘息。随着 COPD 的进展，肺功能逐渐下降，导致呼吸困难。

市场动态：

全球慢性阻塞性肺病(COPD) 治疗市场的成长受到多种因素的推动，例如吸烟率高、全球空气污染水平上升、老年人口增加以及对该疾病和可用治疗方案的认识不断提高。然而，缺乏对慢性阻塞性肺病和肺癌等相关併发症的完全治疗方法可能会阻碍市场的成长。製药公司正在投资研发用于治疗 COPD 的新型生物製药，这可以为市场成长提供丰厚的机会。该公司正在开发肾上腺素自动注射器、支气管扩张剂、吸入性皮质类固醇和联合治疗，以有效治疗 COPD 症状和急性发作。

本研究的主要特点

  • 本报告对全球慢性阻塞性肺病(COPD) 治疗市场进行了详细分析，并提供了预测期 (2025-2032) 的市场规模（十亿美元）和年复合成长率（CAGR%），假设基准年为 2024 年。
  • 它还强调了各个领域的潜在收益成长机会，并说明了该市场的引人注目的投资提案矩阵。
  • 它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
  • 全球慢性阻塞性肺病(COPD) 治疗市场的主要企业是根据公司亮点、产品系列、关键亮点、业绩和策略等参数列出的。
  • 主要企业包括阿斯特捷利康、Orion Corporation、Mylan NV、Teva Pharmaceutical Industries Ltd.、GSK plc、诺华公司、Sunovion Pharmaceuticals, Inc、CHIESI Farmaceutici SpA、Alembic Pharmaceuticals Ltd、Verona Pharmaceuticals、Theravance Biopharma、Alembic Pharmaceuticals Ltd.和基因泰克公司。
  • 本报告的见解将使负责人和企业经营团队能够就未来产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
  • 全球慢性阻塞性肺病(COPD) 治疗市场迎合了该行业的各种相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
  • 相关人员可以透过用于分析全球慢性阻塞性肺病(COPD) 治疗市场的各种策略矩阵来促进决策。

第一章 调查目的与前提条件

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告描述
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章市场动态、法规与趋势分析

  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 影响分析
  • 流行病学
  • 市场趋势
  • 主要进展
  • 监管情景
  • 製造商收益
  • 收购和合作场景
  • 产品发布/核准
  • 资金筹措和投资
  • PEST分析
  • 波特的分析

4. 全球慢性阻塞性肺病(COPD) 治疗市场 - 冠状病毒 (COVID-19) 大流行的影响

  • 整体影响
  • 政府倡议
  • COVID-19 市场影响

第 5 章。 2020 年至 2032 年全球慢性阻塞性肺病(COPD) 治疗市场按药物类别划分（十亿美元）

  • 支气管扩张剂
  • 磷酸二酯酶 4 抑制剂
  • 皮质类固醇
  • 其他的

第六章。 2020-2032 年全球慢性阻塞性肺病(COPD) 治疗市场，依给药途径划分（十亿美元）

  • 口服
  • 吸入

第 7 章。 2020-2032 年全球慢性阻塞性肺病(COPD) 治疗市场按分销管道划分（十亿美元）

  • 医院药房
  • 零售药局
  • 网路药局

第 8 章。 2020 年至 2032 年全球慢性阻塞性肺病(COPD) 治疗市场（按地区划分）（十亿美元）

  • 北美洲
  • 拉丁美洲
  • 欧洲
  • 亚太地区
  • 中东
  • 非洲

第九章 竞争格局

  • 公司简介
    • AstraZeneca
    • Orion Corporation
    • Mylan NV
    • Teva Pharmaceutical Industries Ltd.
    • GSK plc
    • Novartis AG
    • Sunovion Pharmaceuticals, Inc.
    • CHIESI Farmaceutici SpA
    • Alembic Pharmaceuticals Ltd
    • Verona Pharmaceuticals
    • Theravance Biopharma
    • F. Hoffmann-La Roche Ltd
    • Sanofi
    • Boehringer Ingelheim International GmbH
    • Merck &Co., Inc
    • Grifols, SA
    • Almirall, SA
    • Genentech, Inc

第 10 章分析师建议

第 11 章 参考文献与调查方法

  • 参考
  • 调查方法
简介目录
Product Code: CMI2656

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is estimated to be valued at USD 20.35 Bn in 2025 and is expected to reach USD 30.41 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.9% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 20.35 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 5.90% 2032 Value Projection: USD 30.41 Bn
Figure. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Region 2025
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - IMG1

Chronic obstructive pulmonary disease (COPD) refers to a group of lung diseases that cause airflow blockage and breathing-related problems. It includes emphysema and chronic bronchitis. Key causes of COPD include tobacco smoking, exposure to lung irritants in the workplace like dusts and fumes, and air pollution. The main symptoms of COPD include shortness of breath, cough, mucus (sputum) production, and wheezing. As COPD progresses, lung function deteriorates over time, resulting in breathlessness.

Market Dynamics:

Global chronic obstructive pulmonary disease (COPD) treatment market growth is driven by factors such as high prevalence of tobacco smoking, increasing air pollution levels worldwide, rising geriatric population, and a growing awareness about the disease and available therapeutic options. However, lack of complete cure for COPD and related complications like lung cancer can hamper the market growth. Pharmaceutical companies investing in research and development of novel biologic drugs for COPD can offer lucrative opportunities for the market growth. Companies are developing epinephrine auto-injectors, bronchodilators, inhaled corticosteroids and combination therapies to effectively treat COPD symptoms and exacerbations.

Key Features of the Study:

  • This report provides an in-depth analysis of the global chronic obstructive pulmonary disease (COPD) treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
  • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global chronic obstructive pulmonary disease (COPD) treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this include AstraZeneca, Orion Corporation, Mylan N.V., Teva Pharmaceutical Industries Ltd., GSK plc, Novartis AG, Sunovion Pharmaceuticals, Inc., CHIESI Farmaceutici SpA, Alembic Pharmaceuticals Ltd, Verona Pharmaceuticals, Theravance Biopharma, F. Hoffmann-La Roche Ltd, Sanofi, Boehringer Ingelheim International GmbH, Merck & Co., Inc, Grifols, S.A., Almirall, S.A, Genentech, Inc
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global chronic obstructive pulmonary disease (COPD) treatment market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic obstructive pulmonary disease (COPD) treatment market

Detailed Segmentation-

  • By Drug Class:
    • Bronchodilators
    • Beta 2-Agonists
    • Anticholinergics
    • Theophyllines
    • Phosphodiesterase Type 4 Inhibitors
    • Corticosteroids
    • Others
  • By Route of Administration:
    • Oral
    • Inhalation
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • AstraZeneca
    • Orion Corporation
    • Mylan N.V.
    • Teva Pharmaceutical Industries Ltd.
    • GSK plc
    • Novartis AG
    • Sunovion Pharmaceuticals, Inc.
    • CHIESI Farmaceutici SpA
    • Alembic Pharmaceuticals Ltd
    • Verona Pharmaceuticals
    • Theravance Biopharma
    • Hoffmann-La Roche Ltd
    • Sanofi
    • Boehringer Ingelheim International GmbH
    • Merck & Co., Inc
    • Grifols, S.A.
    • Almirall, S.A
    • Genentech, Inc

Table of Contents (TOC)

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Class
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Epidemiology
  • Market Trends
  • Key Developments
  • Regulatory Scenario
  • Manufacturer Revenue
  • Acquisitions and Partnerships Scenario
  • Product Launches/Approvals
  • Funding and Investments
  • PEST Analysis
  • Porter's Analysis

4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the Market

5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Bronchodilators
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Beta 2-Agonists
    • Anticholinergics
    • Theophyllines
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Phosphodiesterase Type 4 Inhibitors
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Corticosteroids
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route of Administration, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Oral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Inhalation
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Region, 2020 - 2032, (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Region, 2021-2032
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
      • North Africa
      • Central Africa
      • South Africa

9. Competitive Landscape

  • Company Profiles
    • AstraZeneca*
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Orion Corporation
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Mylan N.V.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Teva Pharmaceutical Industries Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • GSK plc
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Novartis AG
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Sunovion Pharmaceuticals, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • CHIESI Farmaceutici SpA
    • Alembic Pharmaceuticals Ltd
    • Verona Pharmaceuticals
    • Theravance Biopharma
    • F. Hoffmann-La Roche Ltd
    • Sanofi
    • Boehringer Ingelheim International GmbH
    • Merck & Co., Inc
    • Grifols, S.A.
    • Almirall, S.A
    • Genentech, Inc

10. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

11. References and Research Methodology

  • References
  • Research Methodology
  • About us and Sales Contact